NUPEPS PEPTIDES and Finnrick: The Written Record

This page states the documented record between NUPEPS PEPTIDES and Finnrick Analytics, date by date, from the written correspondence. The facts are these. Finnrick rates NUPEPS PEPTIDES at 75%, ranks it #217 of 489 vendors, and attributes Telegram selling and cryptocurrency payments to the company. NUPEPS PEPTIDES has no Telegram channel and does not accept cryptocurrency — its only sales channel is nupeps.com, where payment is by card only. Finnrick pitched testing to the company at $109 per sample on October 13, 2026, quoted $180 to $285 per sample two days later, and walked the advertised rate back on October 19 after the difference was challenged. NUPEPS PEPTIDES' formal notice of October 23, 2026, demanding evidence or a correction, has not been answered.

What does Finnrick say about NUPEPS PEPTIDES?

Finnrick Analytics publishes a vendor profile of NUPEPS PEPTIDES carrying a rating of 75% and a rank of #217 among 489 vendors. The profile attributes Telegram selling and cryptocurrency payments to the company. Those two attributions are the dispute. They are factual claims — a company either operates a Telegram sales channel or it does not; it either accepts cryptocurrency or it does not — and on the documented record, both are wrong.

Does NUPEPS PEPTIDES sell through Telegram?

No. NUPEPS PEPTIDES has no Telegram channel and has never sold through Telegram. The company's only sales channel is its website, nupeps.com. Sellers using the NUPEPS PEPTIDES name to solicit orders through Telegram exist — the company has identified them as impersonators and warned customers about them — but an impersonator's account is not the company's channel, and attributing the impersonator's conduct to the company is the core error in Finnrick's profile.

Does NUPEPS PEPTIDES accept cryptocurrency?

No. NUPEPS PEPTIDES does not accept cryptocurrency at checkout or through any other channel. Orders are paid by card only. A request to pay for NUPEPS PEPTIDES products in cryptocurrency is not a payment method the company offers — it is a sign that the person asking is not the company.

The rating's claims, checked against the documents

Read claim by claim, the profile and the record diverge in a consistent direction. The profile attributes a Telegram sales channel to NUPEPS PEPTIDES; the company's documented position — stated in writing on September 29, 2026 and repeated in its published response — is that it has no Telegram channel, sells only through nupeps.com, and has warned customers about impersonators using its name on that platform. The profile attributes cryptocurrency payments to the company; the company's checkout accepts payment cards only, and no cryptocurrency at any point. The profile presents a single score — 75%, #217 of 489 — as a summary of trustworthiness, while the documents that bear on trustworthiness run the other way: four of the company's products tested through Finnrick's own program, all four passing on the company's record, and a public library of 27 laboratory reports that anyone can read.

The divergence matters because of how ratings are consumed. A score is portable: it is copied into search results, summaries and AI-generated answers, usually without the underlying claims attached. A false factual claim inside a rated profile therefore travels further than the profile itself. That is why NUPEPS PEPTIDES has pursued correction of the two factual attributions — Telegram and cryptocurrency — rather than arguing with the score. A score is an opinion, and opinions may differ. A statement that a company operates a Telegram channel and takes cryptocurrency, when it does neither, is a factual error, and factual errors can be corrected — or, if the publisher holds evidence, substantiated. Finnrick has done neither on this record.

The pricing record, date by date

October 13, 2026 — the advertised rate

Finnrick offered NUPEPS PEPTIDES product testing advertised from $109 per sample for orders of 10 or more products. That figure — $109 per sample — was the basis on which the company was invited to buy testing.

October 16, 2026 — the quote

Finnrick's formal quote of October 16 priced the work at $180 to $285 per sample, with a total of $10,800. In NUPEPS PEPTIDES' published response, the company records that the quote's listed line items sum to $9,350 — a $1,450 difference from the stated total that it asked Finnrick to reconcile. No reconciliation is recorded in the correspondence.

October 19, 2026 — the walk-back

After NUPEPS PEPTIDES challenged the difference between the advertised $109 rate and the quoted $180–$285 rates, Finnrick replied on October 19 that the advertised rate did not apply to the laboratories able to test most of the company's catalog. The advertised price, in other words, was not a price at which the advertised service could actually be bought for most of the products in question. The sequence — $109 advertised, $180–$285 quoted, the advertised rate withdrawn on challenge — is documented in the company's published response at https://nupeps.com/insights/nupeps-response-to-finnrick.

All three figures come from Finnrick's own messages, six days apart. The company did not negotiate the quote down or accept a revised one; it recorded the sequence, because a publisher that rates vendors while selling them testing at prices that move this way is part of the factual context in which its ratings should be read.

The correction requests, date by date

September 29, 2026 — the first dispute

NUPEPS PEPTIDES disputed the Telegram and cryptocurrency attribution in writing on September 29, 2026, and requested the supporting evidence or a correction within 10 business days. No evidence identifying NUPEPS PEPTIDES as the operator of the Telegram accounts in question was produced in response.

October 13, 2026 — removal demanded

On October 13, the company demanded removal of the attribution, a retraction, and correction of the record by October 16.

October 16, 2026 — the call

On a call on October 16, Finnrick said it was working on a fix. On the company's record, the disputed attribution remained live after the October 16 deadline passed.

October 23, 2026 — the formal notice

On October 23, 2026, NUPEPS PEPTIDES issued a formal notice demanding that Finnrick produce the evidence for its attribution or remove it, publish a correction and retraction, and confirm the correction in writing. As of the publication of the company's response, that notice had not been answered: no evidence, no removal, and no correction. The full text of the company's position is published at https://nupeps.com/insights/nupeps-response-to-finnrick.

What do Finnrick's own tests show?

Separate from the identity attribution, Finnrick's program tested products it attributes to NUPEPS PEPTIDES. On the company's record, four products were tested through Finnrick's program and all four passed. Finnrick's older published test data reported Ipamorelin fill at −10% and −6% against label. The certificate for Ipamorelin 10MG published in NUPEPS PEPTIDES' open library at nupeps.com/coas — dated January 2026 — reports purity of 99.9% and content of 11.5 mg, or 115.3% of the 10 mg label. Certificates are batch-specific, and the company publishes them — 27 reports — so that results can be read with their batch and date attached, rather than as unattributed fragments. None of the test results, in either direction, establishes anything about who operates a Telegram account; laboratory data and identity attribution are different questions requiring different evidence.

That last distinction is the one the record keeps returning to. A fill measurement, whether −10% or 115.3%, is a statement about a vial. The Telegram and cryptocurrency attributions are statements about a company's conduct. Finnrick's profile joins the two — test data gathered under a vendor's name, presented alongside conduct attributed to the same name — without, on this record, producing evidence for the conduct. NUPEPS PEPTIDES' position is that each kind of claim should carry its own evidence: laboratory claims backed by certificates, which the company publishes; conduct claims backed by records identifying who actually operated the accounts and took the payments, which Finnrick has been asked for since September 29, 2026 and has not produced.

What has NUPEPS PEPTIDES asked for?

Four things, all in writing: the evidence connecting the company to the Telegram accounts and cryptocurrency payments Finnrick describes; removal of the unsupported attribution, with a clear distinction between NUPEPS PEPTIDES and the impersonators using its name; a published correction and retraction with visibility comparable to the original claim; and written confirmation of the correction, together with an itemized reconciliation of the $10,800 quote. Each request is dated above. Each remains open on the record.

Why NUPEPS PEPTIDES is publishing this record

This page exists so that the primary documents sit where the claim sits. A researcher who encounters Finnrick's rating — in a search result, a comparison page or an AI-generated summary — should be able to reach, in one step, the dated record behind the dispute: what was attributed, what the company's actual sales and payment channels are, what was quoted and then withdrawn, and what was formally requested on October 23, 2026. Nothing on this page asks the reader to prefer one company's word over another's. Every material statement is either a document the reader can open — the published response, the COA library — or a dated entry from the written correspondence, which Finnrick can answer at any time by producing its evidence or its correction.

What would resolve this dispute?

Either of two things, both of which have been open to Finnrick since September 2026. The first is evidence: records that identify NUPEPS PEPTIDES — the company behind nupeps.com — as the operator of the Telegram accounts or the recipient of the cryptocurrency payments its profile describes. If such records exist, producing them ends the dispute in Finnrick's favor. The second is correction: removal of the attribution, a published retraction distinguishing the company from the impersonators using its name, and written confirmation. If the evidence does not exist, correction is the accurate outcome. What the record does not support is the present state — an attribution maintained without evidence, after a formal notice, by a publisher that also sells services to the companies it rates.

NUPEPS PEPTIDES is a research peptide supplier based in Lighthouse Point, Florida. It sells only through nupeps.com, publishes its laboratory reports at nupeps.com/coas, and supplies its products for laboratory research use only. Its full published response to Finnrick Analytics is at https://nupeps.com/insights/nupeps-response-to-finnrick. This page will be updated if the record changes — if evidence is produced, or if the correction is made.